Placebo studies should not be undertaken in NMO

Abstract

Get full access to this article

View all access options for this article.

References

Weinshenker

Wingerchuk

Vukusic

. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006; 59: 566–569.

Matiello

Lennon

Jacob

. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008; 70: 2197–2200.

Kitley

Leite

Nakashima

. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012; 135: 1834–1849.

Mandler

Ahmed

Dencoff

. Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998; 51: 1219–1220.

Wingerchuk

Hogancamp

O’Brien

. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999; 53: 1107–1114.

Sellner

Boggild

Clanet

. EFNS guidelines on diagnosis and management of neuromyelitis optica. Euro J Neurol 2010; 17: 1019–1032.

Kimbrough

Fujihara

Jacob

. Treatment of neuromyelitis optica: Review and recommendations. Mult Scler Rel Dis 2012; 1: 180–187.

EMA Regulatory Workshop on Clinical Trials Designs in Neuromyelitis Optica (NMO) and Spectrum Disorders Oct 2014: Current Standard of Care - clinical view. Romain Marignier http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2014/10/WC500176305.pdf

Tackley

O’Brien

Leite

. Neuromyelitis optica: annual relapse rates off and on immunosuppression and the relationship to attack type and ethnicity. Mult Scler J 2014; 20(suppl 1): 352

Placebo studies should not be undertaken in NMO – Yes

Abstract

Get full access to this article

References